AMAG Pharmaceuticals, Inc. (AMAG) financial statements (2021 and earlier)

Company profile

Business Address 1100 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 172394329579466
Cash and cash equivalents 113253192274229
Short-term investments 59141137305238
Receivables 94851049286
Inventory, net of allowances, customer advances and progress billings 3227373741
Inventory 3227373741
Other undisclosed current assets 1919121014
Total current assets: 317525482719607
Noncurrent Assets
Operating lease, right-of-use asset 23
Property, plant and equipment 48262429
Intangible assets, net (including goodwill) 4466401,3441,7321,836
Goodwill 423423639639639
Intangible assets, net (excluding goodwill) 242177041,0921,197
Restricted cash and investments 00133
Deferred income tax assets 1
Other noncurrent assets  11113
Other undisclosed noncurrent assets  1   
Total noncurrent assets: 4756501,3711,7601,881
TOTAL ASSETS: 7911,1751,8532,4782,487
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 210144186160111
Accounts payable 27141045
Accrued liabilities 183130175156106
Debt  21 2118
Business combination, contingent consideration, liability 0049  
Deferred revenue and credits423520
Other undisclosed current liabilities 4  9797
Total current liabilities: 214165278313246
Noncurrent Liabilities
Long-term debt and lease obligation 297262735965986
Long-term debt, excluding current maturities 277262735965986
Operating lease, liability 20
Liabilities, other than long-term debt 0151215198
Deferred revenue and credits24155
Deferred tax liabilities, net 24197189
Other liabilities 01234
Business combination, contingent consideration, liability  01  
Other undisclosed noncurrent liabilities    51126
Total noncurrent liabilities: 2972637851,2311,309
Total liabilities: 5114291,0631,5441,555
Stockholders' equity
Stockholders' equity attributable to parent 280747790934932
Common stock 00000
Additional paid in capital 1,2981,2931,2721,2381,234
Accumulated other comprehensive loss (3)(4)(4)(4)(4)
Accumulated deficit (1,015)(542)(478)(300)(298)
Total stockholders' equity: 280747790934932
TOTAL LIABILITIES AND EQUITY: 7911,1751,8532,4782,487

Income statement (P&L) ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 327474610532418
Revenue, net610532418
Cost of revenue
(Cost of Goods and Services Sold)
 (107)(216)(183)(117)(89)
Gross profit: 219258427415330
Operating expenses (666)(305)(720)(336)(219)
Operating income (loss): (447)(47)(293)79111
Nonoperating income (expense) (21)(83)(77)3(8)
Investment income, nonoperating 45332
Other nonoperating income (expense) 0(0)(0)0(9)
Interest and debt expense (26)(36)(11)(73)(64)
Income (loss) from continuing operations before equity method investments, income taxes: (493)(166)(381)940
Other undisclosed income from continuing operations before income taxes 263611  
Income (loss) from continuing operations before income taxes: (468)(130)(370)940
Income tax expense (benefit) 0(40)171(12)(7)
Income (loss) from continuing operations: (468)(169)(199)(2)33
Income from discontinued operations  17   
Net income (loss): (468)(153)(199)(2)33
Other undisclosed net income attributable to parent  87   
Net income (loss) available to common stockholders, diluted: (468)(66)(199)(2)33

Comprehensive Income ($ in millions)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss): (468)(153)(199)(2)33
Comprehensive income (loss): (468)(153)(199)(2)33
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 187(0)0(1)
Comprehensive income (loss), net of tax, attributable to parent: (467)(66)(199)(2)32

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: